ES2184270T3 - Nuevos compuestos. - Google Patents

Nuevos compuestos.

Info

Publication number
ES2184270T3
ES2184270T3 ES98924705T ES98924705T ES2184270T3 ES 2184270 T3 ES2184270 T3 ES 2184270T3 ES 98924705 T ES98924705 T ES 98924705T ES 98924705 T ES98924705 T ES 98924705T ES 2184270 T3 ES2184270 T3 ES 2184270T3
Authority
ES
Spain
Prior art keywords
new compounds
hyperproliferating
proliferating
autoimmune
prophylactic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98924705T
Other languages
English (en)
Inventor
David Cheshire
Andrew Cooke
Martin Cooper
David Donald
Mark Furber
Matthew Perry
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Application granted granted Critical
Publication of ES2184270T3 publication Critical patent/ES2184270T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Use Of Switch Circuits For Exchanges And Methods Of Control Of Multiplex Exchanges (AREA)
  • Valve-Gear Or Valve Arrangements (AREA)
  • Liquid Crystal (AREA)

Abstract

La invención se refiere a nuevos compuestos de fórmula (I), en la que R, R1, R2 y R3 tienen el significado dado en la descripción. El compuesto (I) es útil en el tratamiento (profiláctico) de enfermedades autoinmunes, inflamatorias, proliferantes e hiperproliferantes y enfermedades inmunológicamente inducidas incluyendo el rechazo de órganos o tejidos transplantados y el síndrome de inmunodeficiencia adquirido (SIDA).
ES98924705T 1997-05-28 1998-05-18 Nuevos compuestos. Expired - Lifetime ES2184270T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9702001A SE9702001D0 (sv) 1997-05-28 1997-05-28 Novel compounds

Publications (1)

Publication Number Publication Date
ES2184270T3 true ES2184270T3 (es) 2003-04-01

Family

ID=20407123

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98924705T Expired - Lifetime ES2184270T3 (es) 1997-05-28 1998-05-18 Nuevos compuestos.

Country Status (28)

Country Link
US (2) US6180635B1 (es)
EP (1) EP0991653B1 (es)
JP (1) JP2002500666A (es)
KR (1) KR100561988B1 (es)
CN (1) CN1122037C (es)
AT (1) ATE226205T1 (es)
AU (1) AU723708B2 (es)
BR (1) BR9809481A (es)
CA (1) CA2289509C (es)
CZ (1) CZ297536B6 (es)
DE (1) DE69808765T2 (es)
DK (1) DK0991653T3 (es)
EE (1) EE04018B1 (es)
ES (1) ES2184270T3 (es)
HU (1) HU226627B1 (es)
ID (1) ID28432A (es)
IL (2) IL132763A0 (es)
IS (1) IS1983B (es)
NO (1) NO323752B1 (es)
NZ (1) NZ500853A (es)
PL (1) PL199567B1 (es)
PT (1) PT991653E (es)
RU (1) RU2225410C2 (es)
SE (1) SE9702001D0 (es)
SK (1) SK283589B6 (es)
TR (1) TR199902904T2 (es)
UA (1) UA61111C2 (es)
WO (1) WO1998054190A1 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9801399D0 (sv) 1998-04-21 1998-04-21 Astra Pharma Prod Method and apparatus for filling containers
GB9819382D0 (en) * 1998-09-04 1998-10-28 Cerebrus Ltd Chemical compounds I
GB9819384D0 (en) 1998-09-04 1998-10-28 Cerebrus Ltd Chemical compounds II
EP1280806B1 (en) * 2000-05-04 2004-08-04 AstraZeneca AB THIENO 2,3-d]PYRIMIDINEDIONES AND THEIR USE AS PHARMACEUTICALS
GB2361917A (en) * 2000-05-04 2001-11-07 Astrazeneca Ab Novel thieno[2,3-d]pyrimidinediones
GB2363377B (en) * 2000-06-14 2004-06-09 Astrazeneca Ab Novel thieno[2,3-d]pyrimidinediones and therapeutic uses thereof
WO2002064598A1 (en) * 2001-02-14 2002-08-22 Warner-Lambert Company Llc Thieno'2,3-d pyrimidindione derivatives as matrix metalloproteinase inhibitors
GB0117583D0 (en) * 2001-07-19 2001-09-12 Astrazeneca Ab Novel compounds
GB0118479D0 (en) * 2001-07-28 2001-09-19 Astrazeneca Ab Novel compounds
JP2005518391A (ja) * 2001-12-21 2005-06-23 ノボ　ノルディスク　アクティーゼルスカブ Ｇｋ活性化剤としてのアミド誘導体
CA2744893A1 (en) * 2002-06-27 2004-01-08 Novo Nordisk A/S Aryl carbonyl derivatives as glucokinase activators
US6890923B2 (en) * 2002-12-16 2005-05-10 Astrazeneca Ab Compounds
SE0300119D0 (sv) * 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
US7393854B2 (en) * 2003-01-17 2008-07-01 Astrazeneca Ab Thienopyrimidinedinones and their use in modulation of autoimmune disease
SE0300117D0 (sv) * 2003-01-17 2003-01-17 Astrazeneca Ab Novel Compounds
SE0300120D0 (sv) 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
CA2551324C (en) 2004-01-06 2012-11-27 Novo Nordisk A/S Heteroaryl-ureas and their use as glucokinase activators
US7582769B2 (en) * 2005-07-08 2009-09-01 Novo Nordisk A/S Dicycloalkyl urea glucokinase activators
US7999114B2 (en) * 2005-07-08 2011-08-16 Novo Nordisk A/S Dicycloalkylcarbamoyl ureas as glucokinase activators
AU2006268589B2 (en) 2005-07-14 2011-09-29 Vtv Therapeutics Llc Urea glucokinase activators
EP1989210A2 (en) * 2006-03-02 2008-11-12 Cv Therapeutics, Inc. A2a adenosine receptor antagonists
CN101186612B (zh) * 2006-11-15 2012-10-03 天津和美生物技术有限公司 可抑制细胞释放肿瘤坏死因子的吡咯啉衍生物及其制备和应用
US7776868B2 (en) * 2006-12-01 2010-08-17 Gilead Palo Alto, Inc. Substituted bicyclic and tricyclic thieno[2,3-d]pyrimidines as A2A adenosine receptor antagonists
EP2118083A1 (en) * 2007-01-09 2009-11-18 Novo Nordisk A/S Urea glucokinase activators
EP2099777B1 (en) * 2007-01-11 2015-08-12 Novo Nordisk A/S Urea glucokinase activators
EP2008656A1 (en) * 2007-06-28 2008-12-31 Bergen Teknologioverforing AS Compositions for the treatment of hyperphenylalaninemia
PL2411395T3 (pl) * 2009-03-23 2013-10-31 Glenmark Pharmaceuticals Sa Pochodne furopirymidynodionu jako modulatory TRPA1
BR122019026836B1 (pt) * 2011-11-11 2021-02-23 Gilead Apollo, Llc composto, e, métodos de inibição de acc em uma amostra biológica e em uma planta
JP6268093B2 (ja) * 2012-09-14 2018-01-24 キッセイ薬品工業株式会社 縮合複素環誘導体の製造方法およびその製造中間体
CN105793267B (zh) 2013-10-07 2018-02-06 拜耳制药股份公司 环状噻吩并尿嘧啶甲酰胺类及其用途
UY36586A (es) 2015-03-26 2016-10-31 Bayer Pharma AG Heterociclilmetiltienouracilos y uso de los mismos
AR106472A1 (es) 2015-10-26 2018-01-17 Gilead Apollo Llc Inhibidores de acc y usos de los mismos
CN108349994B (zh) 2015-11-25 2021-06-22 吉利德阿波罗公司 三唑acc抑制剂及其用途
PL3380480T3 (pl) 2015-11-25 2023-05-08 Gilead Apollo, Llc Pirazolowe inhibitory acc i ich zastosowania
JP2018536660A (ja) 2015-11-25 2018-12-13 ギリアド アポロ， エルエルシー エステルａｃｃ阻害剤およびその使用
MX2018006285A (es) 2015-11-25 2018-09-07 Gilead Apollo Llc Composiciones fungicidas que contienen derivados de 2,4-dioxido-1,4-dihidrotieno[2,3-d] pirimidina.
CA3015526C (en) 2016-03-02 2022-10-04 Gilead Apollo, Llc Solid forms of a thienopyrimidinedione acc inhibitor and methods for production thereof
WO2018041771A1 (de) 2016-09-02 2018-03-08 Bayer Pharma Aktiengesellschaft (1-methylcyclopropyl)methyl-substituierte thienouracile und ihre verwendung
EP3515919A1 (de) * 2016-09-23 2019-07-31 Bayer Aktiengesellschaft N3-cyclisch substituierte thienouracile und ihre verwendung
EP4122464B1 (en) 2017-03-28 2024-05-15 Gilead Sciences, Inc. Therapeutic combinations for treating liver diseases
AU2019287437A1 (en) 2018-06-12 2020-09-10 Vtv Therapeutics Llc Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0335979A4 (en) * 1987-09-16 1992-02-26 Taiho Pharmaceutical Company, Limited Thienopyrimidine derivatives
TW276256B (es) 1993-08-26 1996-05-21 Takeda Pharm Industry Co Ltd
FR2750862B1 (fr) * 1996-07-12 1998-10-16 Dupin Jean Pierre Utilisation d'heterocycles diazotes fusionnes avec un systeme aromatique ou heteroaromatique pour le traitement des maladies thrombo-emboliques

Also Published As

Publication number Publication date
NO323752B1 (no) 2007-07-02
NO995810L (no) 2000-01-27
SK283589B6 (sk) 2003-10-07
NZ500853A (en) 2001-05-25
RU2225410C2 (ru) 2004-03-10
HUP0003355A3 (en) 2003-03-28
AU723708B2 (en) 2000-09-07
CA2289509A1 (en) 1998-12-03
AU7680898A (en) 1998-12-30
BR9809481A (pt) 2000-06-20
ID28432A (id) 2001-05-24
SE9702001D0 (sv) 1997-05-28
IL132763A (en) 2007-03-08
EP0991653B1 (en) 2002-10-16
SK151399A3 (en) 2000-05-16
KR100561988B1 (ko) 2006-03-17
HU226627B1 (en) 2009-05-28
PT991653E (pt) 2003-02-28
PL199567B1 (pl) 2008-10-31
HUP0003355A2 (hu) 2001-02-28
WO1998054190A1 (en) 1998-12-03
US6180635B1 (en) 2001-01-30
IS5264A (is) 1999-11-23
CZ297536B6 (cs) 2007-01-03
DE69808765D1 (de) 2002-11-21
DE69808765T2 (de) 2003-07-24
EP0991653A1 (en) 2000-04-12
CZ420199A3 (cs) 2000-07-12
EE9900539A (et) 2000-06-15
DK0991653T3 (da) 2003-01-06
CA2289509C (en) 2007-10-02
JP2002500666A (ja) 2002-01-08
CN1264382A (zh) 2000-08-23
ATE226205T1 (de) 2002-11-15
PL337126A1 (en) 2000-07-31
TR199902904T2 (xx) 2000-06-21
CN1122037C (zh) 2003-09-24
IL132763A0 (en) 2001-03-19
UA61111C2 (uk) 2003-11-17
IS1983B (is) 2005-01-14
NO995810D0 (no) 1999-11-26
US6342502B1 (en) 2002-01-29
EE04018B1 (et) 2003-04-15
KR20010013107A (ko) 2001-02-26

Similar Documents

Publication Publication Date Title
ES2184270T3 (es) Nuevos compuestos.
NL350077I2 (nl) Cyprosulfamide
AR001440A1 (es) Nuevos taxoides, su preparación y composiciones farmacéuticas que los contienen.
DE69124371D1 (de) Typ-iv-dipeptidyl-aminopeptidase-inhibitoren
HUP0004592A2 (hu) VCAM-1 expresszió gátlására alkalmas vegyületek és eljárások
ATE242213T1 (de) Neue 4-(oxyalkoxyphenyl)-3-oxy-piperidine zur behandlung von herz- und niereninsuffizienz
DE69503647T2 (de) Aminoheterocyclische derivate als antithrombotische oder antikoagulierende mittel
ATE196765T1 (de) Dihydrobenzofurane
ES2058185T3 (es) Derivados de camptotecina y procedimiento para su preparacion.
DE69823344D1 (de) Substituierte benzimidazol-derivaten und ihre verwendung zur behandlung retroviraler infektionen
ES2031523T3 (es) Agentes diureticos de glutaramida espiro-sustituida.
CR6540A (es) Trifluorobutenos nematicidas
NZ325449A (en) Naphthyl-substituted benzimidazole derivatives as anticoagulants
ES2178036T3 (es) Derivados de ciclosporina, su preparacion y las composiciones farmaceuticas que le contienen.
ES2134777T3 (es) Nuevos compuestos de sulfonilo.
TR199900486T2 (xx) Aziniloksi ve fenoksi-diaril-karbonasit t�revleri.
EA200300392A1 (ru) Производные пиперазина с мостиковой связью
DE3880194D1 (de) Zyklisches antikoagulierendes peptid.
FR2599752B1 (fr) Variants de l'alpha1- antitrypsine utiles notamment comme inhibiteurs de la kallikreine
TR200402070T4 (tr) Siklobüten-dion türevleri ve bunların damar sertliği tedavisinde kullanımı
DK0775158T3 (da) Cyclopeptolider
ATE108801T1 (de) Antikoagulierende peptid-alkohole.
AR007052A1 (es) Un derivado de carbohidrato, su uso y una composicion farmaceutica que lo comprende
NO930234L (no) Antikoagulerende midler
ES2108004T3 (es) Nuevas alquil piperidinas sustituidas y su empleo como inhibidores de la sintesis de colesterol.